u/enzo_ferrari

The transaction hash is the canonical receipt: it is public, verifiable by either party, and it is what a support query should quote.

Accused the wrong party publicly and it was my storage. Correcting it here was the most uncomfortable post I have made and the right one.

It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.

Clearance took three days and the carrier took nine. I had been blaming the wrong half for two years.

Same view — private and provincial plans are genuinely different processes with different appeal routes.

the criteria change at plan renewal and nobody announces it

quantity limits are as common a barrier as coverage itself

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

a rejected claim is not the same as a denied authorization

summer and winter are different lanes with the same name

A lane is an origin, a destination, a carrier and a season. Change any one and the distribution changes, which is why supplier-level shipping averages are close to meaningless.

Correction: that address format is not the chain you named. Worth checking before anybody follows this.

confirmations are the only status that means anything

This is the check that prevents the only genuinely unrecoverable mistake in this thread.

Started keeping the trial identifiers straight in a note file because I kept mixing up two programmes in the same sentence.

Same lane, four orders, 8 to 15 days, all four within a couple of days of the quote. That consistency is the actual finding.

the appendix is where the interesting tables live

keep the hash, it is the only receipt that exists

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

Keep every transaction hash in a note file with the order reference. It has resolved two queries instantly.

ask which lines are actually held in the regional warehouse

This. Intention-to-treat versus completer analysis routinely moves the headline by several points.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

That figure is the starting material purity, not the finished preparation potency. Two different tests.

This. A test transaction on a large order costs a fraction of the fee and removes the whole class of risk.

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.